DermTech Announces Release Date for Second-Quarter 2023 Financial Results
17 Juillet 2023 - 2:00PM
Business Wire
DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a
leader in precision dermatology enabled by a non-invasive skin
genomics technology, will host a conference call and webcast on
Thursday, August 3, 2023 at 5:00 p.m. Eastern Time (ET) to discuss
the Company's second-quarter 2023 operating and financial results.
In advance of the call on August 3, 2023, DermTech will issue its
second-quarter 2023 earnings press release.
For participants interested in asking questions during the
teleconference, please register using the following link. After
registering for the event, a confirmation e-mail will be sent with
a meeting invitation and access information. Registration is open
during the live teleconference, but advance registration is
advised.
Conference Call Registration
For participants interested in listening only, please register
for the webcast using the following link.
Webcast Registration
For those unable to participate in the live call and webcast, a
webcast replay will be available on the Company’s website shortly
after the conclusion of the call.
About DermTech
DermTech is a leading genomics company in dermatology and is
creating a new category of medicine, precision dermatology, enabled
by its non-invasive skin genomics technology. DermTech’s mission is
to improve the lives of millions by providing non-invasive
precision dermatology solutions that enable individualized care.
DermTech provides genomic analysis of skin samples collected
non-invasively using our Smart StickersTM. DermTech markets and
develops products that facilitate the early detection of skin
cancers. For additional information, please visit DermTech.
Forward-Looking Statements
This press release includes “forward-looking statements” within
the meaning of the “safe harbor” provisions of the Private
Securities Litigation Reform Act of 1995. The expectations,
estimates, and projections of DermTech may differ from its actual
results and consequently, you should not rely on these
forward-looking statements as predictions of future events. Words
such as “expect,” “estimate,” “project,” “budget,” “forecast,”
"outlook," “anticipate,” “intend,” “plan,” “may,” “will,” “could,”
“should,” “believe,” “predict,” “potential,” “continue,” and
similar expressions are intended to identify such forward-looking
statements. These forward-looking statements include, without
limitation, expectations and evaluations with respect to: the
performance, patient benefits, cost- effectiveness,
commercialization and adoption of DermTech’s products and the
market opportunity for these products, DermTech’s positioning and
potential growth, financial outlook and future financial
performance, ability to monetize existing demand by increasing its
proportion of reimbursed billable samples, ability to maintain or
improve its operating efficiency and reduce operating expenses, the
sufficiency of DermTech’s cash resources and runway and ability to
access capital to fund its operating plan, the sufficiency of its
cash resources to fund planned operations for the anticipated
period, anticipated annual cash savings to be realized from the
restructuring, implications and interpretations of any study
results, and expectations regarding agreements with or
reimbursement or cash collection patterns from Medicare, government
payers or commercial payers and related billing practices or number
of covered lives. These forward-looking statements involve
significant risks and uncertainties that could cause the actual
results to differ materially from the expected results. Most of
these factors are outside of the control of DermTech and are
difficult to predict. Factors that may cause such differences
include, but are not limited to: (1) the outcome of any legal
proceedings that may be instituted against DermTech; (2) DermTech’s
ability to obtain additional funding to develop and market its
products; (3) the existence of favorable or unfavorable clinical
guidelines for DermTech’s tests; (4) the reimbursement of
DermTech’s tests by Medicare, government payers and commercial
payers; (5) the ability of patients or healthcare providers to
obtain coverage of or sufficient reimbursement for DermTech’s
products; (6) DermTech’s ability to grow, manage growth and retain
its key employees and maintain or improve its operating efficiency
and reduce operating expenses; (7) changes in applicable laws or
regulations; (8) the market adoption and demand for DermTech’s
products and services together with the possibility that DermTech
may be adversely affected by other economic, business, and/or
competitive factors; and (9) other risks and uncertainties included
in the “Risk Factors” section of the most recent Annual Report on
Form 10-K filed by DermTech with the Securities and Exchange
Commission (the “SEC”), and other documents filed or to be filed by
DermTech with the SEC, including subsequently filed reports.
DermTech cautions that the foregoing list of factors is not
exclusive. You should not place undue reliance upon any forward-
looking statements, which speak only as of the date made. DermTech
does not undertake or accept any obligation or undertaking to
release publicly any updates or revisions to any forward-looking
statements to reflect any change in its expectations or any change
in events, conditions, or circumstances on which any such statement
is based.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230717436087/en/
Steve Kunszabo DermTech (858) 291-1647
steve.kunszabo@dermtech.com
DermTech (NASDAQ:DMTK)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
DermTech (NASDAQ:DMTK)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024